Reuters reported on January 25, 2009, the U.S. Food and Drug Administration’s recent approval of liraglutide (brand name: Victoza).
It joins Byetta (exenatide) as the second GLP-1 (glucagon-like peptide-1) analog available in the U.S. Both are injections and work by stimulating the release of insulin by pancreas beta cells when blood sugar is too high.
The FDA indicated liraglutide is not generally a first-choice drug for diabetes.
It’s always good to have options.